PETROS PHARMACEUTICALS INC (PTPI) Stock Price, Quote, News and Overview
NASDAQ:PTPI - Nasdaq - US71678J2096 - Common Stock - Currency: USD
PTPI Quote, Performance and Key Statistics
0.054
+0 (+5.47%)
The current stock price of PTPI is 0.054 USD. In the past month the price decreased by -51.35%. In the past year, price decreased by -91.56%.
PTPI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 68.04 | 838.54B | ||
| JNJ | JOHNSON & JOHNSON | 15.38 | 372.51B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 17.99 | 275.58B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.12 | 221.49B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.76 | 215.69B | ||
| MRK | MERCK & CO. INC. | 10.62 | 208.21B | ||
| PFE | PFIZER INC | 7.37 | 129.99B | ||
| SNY | SANOFI-ADR | 13.59 | 128.08B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.53 | 97.47B | ||
| GSK | GSK PLC-SPON ADR | 8.6 | 75.84B | ||
| ZTS | ZOETIS INC | 25.92 | 68.46B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.67 | 47.30B |
Related stock screener links
About PTPI
Company Profile
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. The company is headquartered in New York City, New York and currently employs 18 full-time employees. The company went IPO on 2020-12-02. The firm is pursuing access to its flagship prescription erectile dysfunction (ED) therapy, Stendra, via potential OTC designation. Stendra is a Phosphodiesterase - 5 (PDE - 5) inhibitor prescription medication for the treatment of ED and is the only patent protected PDE-5 inhibitor on the market. Stendra offers the ED therapeutic landscape a valuable addition as an oral ED therapy that may be taken once daily as early as approximately 15 minutes prior to sexual engagement, with or without food, when using the 100mg or 200mg dosing, subject to certain contraindications and limitations common among PDE-5 inhibitors. The company also markets its own line of medical devices intended for ED treatment through its subsidiaries, Timm Medical and PTV, including the VED systems marketed as Osbon ErecAid and PosTVac.
Company Info
PETROS PHARMACEUTICALS INC
1185 Avenue Of The Americas, 3Rd Floor, Suite 570
New York City NEW YORK 10036 US
CEO: John D. Shulman
Employees: 21
Company Website: https://www.petrospharma.com/
Investor Relations: http://irdirect.net/PTPI/sec_filings
Phone: 19732420005
PETROS PHARMACEUTICALS INC / PTPI FAQ
What is the stock price of PETROS PHARMACEUTICALS INC today?
The current stock price of PTPI is 0.054 USD. The price increased by 5.47% in the last trading session.
What is the ticker symbol for PETROS PHARMACEUTICALS INC stock?
The exchange symbol of PETROS PHARMACEUTICALS INC is PTPI and it is listed on the Nasdaq exchange.
On which exchange is PTPI stock listed?
PTPI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PETROS PHARMACEUTICALS INC stock?
7 analysts have analysed PTPI and the average price target is 1.02 USD. This implies a price increase of 1788.89% is expected in the next year compared to the current price of 0.054. Check the PETROS PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PETROS PHARMACEUTICALS INC worth?
PETROS PHARMACEUTICALS INC (PTPI) has a market capitalization of 2.89M USD. This makes PTPI a Nano Cap stock.
How many employees does PETROS PHARMACEUTICALS INC have?
PETROS PHARMACEUTICALS INC (PTPI) currently has 21 employees.
Is PETROS PHARMACEUTICALS INC (PTPI) expected to grow?
The Revenue of PETROS PHARMACEUTICALS INC (PTPI) is expected to grow by 0.76% in the next year. Check the estimates tab for more information on the PTPI EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PETROS PHARMACEUTICALS INC (PTPI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PTPI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PTPI, evaluating the profitability, health, valuation and growth aspects
- PETROS PHARMACEUTICALS INC (PTPI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PETROS PHARMACEUTICALS INC (PTPI) Sales and EPS estimates to see what analysts future expectations are.
- PETROS PHARMACEUTICALS INC (PTPI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PETROS PHARMACEUTICALS INC (PTPI) Insider and Institutional Ownership to learn about the owners and their transactions.
- PETROS PHARMACEUTICALS INC (PTPI) Stock Chart to make your own analysis
- PETROS PHARMACEUTICALS INC (PTPI) Latest news and press-releases to stay up to date.
Does PETROS PHARMACEUTICALS INC (PTPI) stock pay dividends?
PTPI does not pay a dividend.
What is the Price/Earnings (PE) ratio of PETROS PHARMACEUTICALS INC (PTPI)?
PETROS PHARMACEUTICALS INC (PTPI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.66).
What is the Short Interest ratio of PETROS PHARMACEUTICALS INC (PTPI) stock?
The outstanding short interest for PETROS PHARMACEUTICALS INC (PTPI) is 2.95% of its float. Check the ownership tab for more information on the PTPI short interest.
PTPI Technical Analysis
PTPI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to PTPI. PTPI has a bad profitability rating. Also its financial health evaluation is rather negative.
PTPI Financial Highlights
Over the last trailing twelve months PTPI reported a non-GAAP Earnings per Share(EPS) of -3.66. The EPS increased by 64.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -251.96% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PTPI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to PTPI. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 48.83% and a revenue growth 0.76% for PTPI